Fox Chase researchers win $1.4M DoD Prostate Cancer Health Equity Grant

Daniel Geynisman named editor-in-chief of JNCCN

Daniel M. Geynisman was named the editor-in-chief of JNCCN—Journal of the National Comprehensive Cancer Network.

May 17, 2024

DOD Melanoma Research Program funding opportunities for FY24

The FY24 Defense Appropriations Act is anticipated to provide funding for the Melanoma Research Program to support innovative, high-impact melanoma research.

May 17, 2024

Vol.50 No.20

Clinical Roundup

AI-based biomarker stratifies metastasis risk in patients with BCR post-prostatectomy

ArteraAI has validated its first multimodal artificial intelligence digital pathology-based post-radical prostatectomy biomarker for stratifying risk of metastasis and identifying differential absolute benefit for the addition of hormone therapy to salvage radiation therapy in radical prostatectomy patients with biochemical recurrence.

May 10, 2024

Vol.50 No.19

Clinical Roundup

AI tool predicts success of focal therapy for prostate cancer

Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care, unveiled the results of a new UCLA study examining the role of AI in identifying tumor margins and predicting the efficacy of focal therapy treatments.

May 10, 2024

Vol.50 No.19

In the Archives

Paul Grotzinger and Jerry Hanks: Fox Chase pioneers

Fox Chase Cancer Center has contributed two articles to the Cancer History Project, documenting the impact of Paul Grotzinger and Gerald “Jerry” Hanks.

April 26, 2024

Vol.50 No.17